Michael J Overman, MD
Disclosures: Consulting Fee-Merck and Company, Inc.-|Consulting Fee-AbbVie-|Consulting Fee-Agilvax-|Consulting Fee-Takeda Pharmaceuticals, Inc.-|Consulting Fee-Acrotech Biopharma-|Consulting Fee-Novartis Pharmaceuticals Corp-|Consulting Fee-Nouscom- - 07/30/2021

Michael Overman is a Professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center. He is also the Cancer Medicine Executive Director for the Cancer Network.

Dr. Overman received his medical degree from John Hopkins School of Medicine. He did his Internal Medicine training at Harbor UCLA and his Medical Oncology/Hematology fellowship at MD Anderson Cancer Center. He joined faculty at MD Anderson Cancer Center in 2007.  Recently he received a Master of Science in Health Care Transformation from the University of Texas, Austin in 2020.


Dr Overman’s research efforts have focused upon novel clinical trials in both pancreatic and intestinal cancers.  In particular, he has been instrumental in exploring the use of immune-therapy in the subset of patients with deficient mismatch repair.